newsfilter
← Latest News
Business Wire·

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal

Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care